Company intelligence / Profile preview
EnnoDC
Paris area likely, Île-de-France, Franceennodc.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
EnnoDC has developed a first-in-class dendritic cell-targeting immunotherapy platform, with its lead asset CD40HVac in Phase I/IIa trials for HPV16+ oropharyngeal cancer. The technology has also entered clinical development for infectious diseases such as HIV and COVID. The approach aims to deliver more targeted immune responses by directly stimulating dendritic cells, potentially reducing side effects and improving efficacy compared to existing therapies.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Fusion proteinsMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Baylor Institute for Immunology Research, Dallas TXMoffitt Cancer Center, USGustave Roussy Cancer Campus, FranceParis Saclay Cancer Cluster support
Beyond the preview
Go deeper on EnnoDC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EnnoDC.